Evolution of hepatitis C virus quasispecies during repeated treatment with the NS3/4A protease inhibitor telaprevir.

Susser, Simone; Flinders, Mathieu; Reesink, Henk W; Zeuzem, Stefan; Lawyer, Glenn; Ghys, Anne; Van Eygen, Veerle; Witek, James; De Meyer, Sandra; Sarrazin, Christoph

Susser, Simone; Flinders, Mathieu; Reesink, Henk W; Zeuzem, Stefan; Lawyer, Glenn; Ghys, Anne; Van Eygen, Veerle; Witek, James; De Meyer, Sandra; Sarrazin, Christoph.

Afiliación

Susser S; Johann Wolfgang Goethe-University Medical Center, Frankfurt am Main, Germany.
Flinders M; Max Planck Institute for Informatics, Saarbrücken, Germany.
Reesink HW; Academic Medical Center, Amsterdam, The Netherlands.
Zeuzem S; Johann Wolfgang Goethe-University Medical Center, Frankfurt am Main, Germany.
Lawyer G; Max Planck Institute for Informatics, Saarbrücken, Germany.
Ghys A; Janssen Infectious Diseases, Beerse, Belgium.
Van Eygen V; Janssen Infectious Diseases, Beerse, Belgium.
Witek J; Janssen Research & Development LLC, New Jersey, USA.
De Meyer S; Janssen Infectious Diseases, Beerse, Belgium.
Sarrazin C; Johann Wolfgang Goethe-University Medical Center, Frankfurt am Main, Germany sarrazin@em.uni-frankfurt.de.

Antimicrob Agents Chemother ; 59(5): 2746-55, 2015 May.

Article en En | MEDLINE | ID: mdl-25712364

Asunto(s)

Antivirales/uso terapéutico; Hepacivirus/efectos de los fármacos; Hepacivirus/patogenicidad; Oligopéptidos/uso terapéutico; Proteínas no Estructurales Virales/antagonistas & inhibidores; Método Doble Ciego; Hepatitis C; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Oligopéptidos / Proteínas no Estructurales Virales / Hepacivirus Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2015 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google